Clinical Effectiveness of Intravitreal Fluocinolone Acetonide (FAc) (ILUVIEN™) in Patients With Diabetic Macular Oedema (DMO) Refractory to Prior Therapy: The Manchester Experience

Ophthalmology and Therapy- United Kingdom

doi 10.1007/s40123-019-0197-3

Full Text

Abstract

Available in

Date

July 15, 2019

Authors

Publisher

Springer Science and Business Media LLC

Related search

Real-World Experience of Fluocinolone Acetonide (0.2 Μg/Day) Intravitreal Implant in the Treatment of Diabetic Macular Oedema

European Ophthalmic Review

2015

English

Clinical Evaluation of Intravitreal Triamcinolone Acetonide in Diabetic Macular Oedema

Scholars Journal of Applied Medical Sciences

2016

English

Fluocinolone Acetonide (0.19 Mg) Intravitreal Implant Reduces Treatment Burden and Improves Practice Resource Utilisation for Patients With Diabetic Macular Oedema

BMJ Open Ophthalmology

Ophthalmology

2020

English

Three Year Real‐life Outcomes From the Use of the Fluocinolone Acetonide Implant (Iluvien) in the Treatment of Refractory DMO

English

Efficacy and Safety of Corticosteroid Implant (Fluocinolone Acetonide (FAc) 0.2 Μ G/Day, Iluvien ® ) for Management of Diabetic Macular Edema (DME): A Real‐life Study

English

Fluocinolone Acetonide Intravitreal Implant (Retisert® ) in the Treatment of Sight Threatening Macular Oedema of Juvenile Idiopathic Arthritis-Related Uveitis

English

Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN®) in Patients With Diabetic Macular Edema: 10 Eyes With 12 Months Follow-Up

Ophthalmology and Therapy

Ophthalmology

2016

English

Comparison of Data Characterising the Clinical Effectiveness of the Fluocinolone Intravitreal Implant (ILUVIEN) in Patients With Diabetic Macular Edema From the Real World, Non-Interventional ICE-UK Study and the FAME Randomized Controlled Trials

Current Medical Research and Opinion

Medicine

2019

English

Three-Year Results From the Retro-Ideal Study: Real-World Data From Diabetic Macular Edema (DME) Patients Treated With ILUVIEN® (0.19 Mg Fluocinolone Acetonide Implant)

European Journal of Ophthalmology

Medicine

Ophthalmology

2019

English

Amanote Research

Clinical Effectiveness of Intravitreal Fluocinolone Acetonide (FAc) (ILUVIEN™) in Patients With Diabetic Macular Oedema (DMO) Refractory to Prior Therapy: The Manchester Experience

Ophthalmology and Therapy- United Kingdom

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Real-World Experience of Fluocinolone Acetonide (0.2 Μg/Day) Intravitreal Implant in the Treatment of Diabetic Macular Oedema

Clinical Evaluation of Intravitreal Triamcinolone Acetonide in Diabetic Macular Oedema

Fluocinolone Acetonide (0.19 Mg) Intravitreal Implant Reduces Treatment Burden and Improves Practice Resource Utilisation for Patients With Diabetic Macular Oedema

Three Year Real‐life Outcomes From the Use of the Fluocinolone Acetonide Implant (Iluvien) in the Treatment of Refractory DMO

Efficacy and Safety of Corticosteroid Implant (Fluocinolone Acetonide (FAc) 0.2 Μ G/Day, Iluvien ® ) for Management of Diabetic Macular Edema (DME): A Real‐life Study

Fluocinolone Acetonide Intravitreal Implant (Retisert® ) in the Treatment of Sight Threatening Macular Oedema of Juvenile Idiopathic Arthritis-Related Uveitis

Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN®) in Patients With Diabetic Macular Edema: 10 Eyes With 12 Months Follow-Up

Comparison of Data Characterising the Clinical Effectiveness of the Fluocinolone Intravitreal Implant (ILUVIEN) in Patients With Diabetic Macular Edema From the Real World, Non-Interventional ICE-UK Study and the FAME Randomized Controlled Trials

Three-Year Results From the Retro-Ideal Study: Real-World Data From Diabetic Macular Edema (DME) Patients Treated With ILUVIEN® (0.19 Mg Fluocinolone Acetonide Implant)